Compositions having improved bioavailability
AssigneePfizer Inc.
InventorMichael John Humphrey
Life of this patent
Estimating the term…
Abstract
A composition comprising eletriptan and a p-glycoprotein (p-gp) inhibitor useful for the treatment of migraine. The bioavailability of eletriptan can be increased by co-administering eletriptan with a p-gp inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit. Also provided is a method of treating migraine using said composition or sequential administration of components.
Claims24
A method of treating migraine in a subject comprising administering to said subject an amount of a composition comprising eletriptan in combination with a p-gp inhibitor effective to treat migraine in said subject, or administering in sequence to said subject eletriptan and a p-gp inhibitor, each in an amount effective to treat migraine in said subject.
A pharmaceutical composition comprising eletriptan, a p-gp inhibitor and a pharmaceutically acceptable carrier, diluent, or excipient.
A kit comprising
- (1) a therapeutically effective amount of a composition comprising eletriptan and a pharmaceutically acceptable carrier, diluent, or excipient, in a first dosage form;
- (2) a therapeutically effective amount of a composition comprising a compound which is a p-gp inhibitor and a pharmaceutically acceptable carrier, diluent, or excipient, in a second dosage form;
- and
- (3) a container for containing said first and second dosage forms.
Dependencies are inferred from the claim text.